Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
McKesson
AstraZeneca
Harvard Business School
Cipla
Fish and Richardson
Johnson and Johnson
Express Scripts
Cantor Fitzgerald

Generated: April 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021025

« Back to Dashboard

NDA 021025 describes EXELON, which is a drug marketed by Novartis and is included in three NDAs. It is available from three suppliers. There are two patents protecting this drug and four Paragraph IV challenges. Additional details are available on the EXELON profile page.

The generic ingredient in EXELON is rivastigmine. There are thirty-two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the rivastigmine profile page.
Summary for 021025
Tradename:EXELON
Applicant:Novartis
Ingredient:rivastigmine tartrate
Patents:0
Therapeutic Class:Antidementia Agents
Formulation / Manufacturing:see details

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:SOLUTION;ORALStrengthEQ 2MG BASE/ML
Approval Date:Apr 21, 2000TE:RLD:No

Expired US Patents for NDA 021025

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis EXELON rivastigmine tartrate SOLUTION;ORAL 021025-001 Apr 21, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis EXELON rivastigmine tartrate SOLUTION;ORAL 021025-001 Apr 21, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Dow
US Army
Express Scripts
McKinsey
Boehringer Ingelheim
Argus Health
Colorcon
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.